Helsinki-based Gosta Labs just banked €7.5 million in seed funding to scale its AI platform that automates oncology documentation—freeing doctors from hours of typing and letting them focus on patients instead.
Voima Ventures led the oversubscribed round, with COR Group, the Aho family, Reaktor, and medtech angels joining the cap table.
Who Are These Founders?
Lauri Sippola and Henri Viertolahti sold their first cancer-tech startup, Kaiku Health, to Swedish radiotherapy giant Elekta in 2020. They built Gosta Labs in 2023 to attack the same problem from a different angle: using AI to turn patient visits into structured clinical notes instantly.
Dr. Lionel Hadjadjeba (CMO) and Reetta Arokoski (COO) round out the leadership team with deep oncology and regulatory experience. This is a crew that knows how to build medical-grade software and sell it globally.
What Gosta's AI Actually Does?
Gosta's platform listens to oncology consultations and auto-generates clinical notes, grades toxicities, maps patient journeys, and links treatment decisions to international guidelines.
At ESMO 2025, oncologists using the system completed follow-up documentation in under two minutes—down from 15–30 minutes of manual work.
The AI is live in Finland, Switzerland, the Baltics, and Australia, with early adopters reporting massive time savings and fewer documentation errors.
The €7.5M Seed Breakdown
👉 This is actually Gosta's third raise in 18 months: €1.7M pre-seed (2024), €4M seed (September 2025), and now a €7.5M extension (November 2025). Total funding sits at roughly €10M.
The money goes toward:
Why This Oncology AI Deal Hits Different?
Cancer cases are exploding—35 million annually by 2050—while oncologists drown in paperwork. Most AI health startups promise the moon; Gosta delivers measured time savings and already has customers live.
Voima's Jussi Sainiemi said it best: “While AI hype is everywhere, Gosta delivers actual value.” That's investor-speak for “this isn't vaporware.”
Quick Funding Facts
Who led Gosta's seed round?
Voima Ventures, with COR Group, the Aho family, Reaktor, and angels.
What will Gosta use the capital for?
Scale AI, get medical certifications, and expand globally.
What's the founders' track record?
Sold Kaiku Health to Elekta in 2020; built global cancer-care software used worldwide.
Company Snapshot
The Bottom Line
Gosta Labs isn't chasing AI hype—it's solving a real pain point for cancer doctors. The founders have done it before, the tech is already saving time in clinics, and the market need is only growing.
The challenge? Scaling sales across fragmented healthcare systems while keeping regulators happy. If they pull it off, this seed round tees up a monster Series A in 12–18 months.
Connect With Gosta Labs
| Channel | URL |
|---|---|
| Website | gostalabs.com |
| linkedin.com/company/gostalabs | |
| Lauri Sippola, CEO- lauri@gostalabs.com | |
| Product | gostalabs.com/product |
